U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905197) titled 'A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)' on March 25.
Brief Summary: This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: DZD6008
Daily dose of DZD6008
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Dizal Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....